In addition to preserving hemostasis, fibrinogen assembly on leukocyte
s mediates inflammatory responses and may aberrantly contribute to vas
cular injury, In this study, we used real-time intravital video micros
copy in exposed rabbit mesentery to investigate the potential role of
fibrinogen on leukocyte adherence mechanisms, in vivo. At physiologic
concentrations of 0.15 to 0.5 mg/ml, human fibrinogen dose-dependently
enhanced by threefold to fivefold the adhesion of chemoattractant-sti
mulated monocytic HL-60 cells to rabbit mesenteric endothelium, by act
ing as a bridging molecule between the two cell types. Fibrinogen-depe
ndent intercellular bridging occurred in venules, but not in arteriole
s or capillaries (1), was optimal at reduced flow shear forces (range:
0.77 to 2.79 dyne/cm(2)) (2), and produced a firm attachment of monoc
ytic cells to endothelium, rather than transient rolling (3). Consiste
nt with this model, rabbit fibrinogen failed to support human leukocyt
e adhesion, while human fibrinogen enhanced monocytic cell attachment
to rabbit endothelial cells in vitro, in a reaction indistinguishable
from that observed with human endothelium. Antagonists of the recently
described association of fibrinogen with intercellular adhesion molec
ule-1 (ICAM-1), including monoclonal antibodies (MoAbs) LB-2 or 2D5, o
r the fibrinogen gamma 3 peptide gamma Asn(117)-Ala(133), blocked fibr
inogen-dependent leukocyte-endothelium interaction in vitro or in vivo
, respectively, while a control nonbinding antibody or the fibrinogen
L10 peptide gamma Leu(402)-Val(411) were ineffective. These data sugge
st that simultaneous assembly of fibrinogen on leukocytes and endothel
ial ICAM-1 provides a pathway of intercellular adhesion which may act
in concert with beta(2) integrins to stabilize firm leukocyte attachme
nt to endothelium, in vivo. Given the recognized role of fibrinogen as
a major risk factor for atherosclerosis, this mechanism may directly
contribute to thrombus formation and endothelial cell damage in vascul
ar diseases. (C) 1996 by The American Society of Hematology.